Real‐world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma
Akira Takahashi, Naoya Yamazaki(Tokyo National Hospital), Eiji Nakano, Kenjiro Namikawa(Tokyo Metropolitan Komagome Hospital), Haruki Mizuta, Shunichi Jinnai, Kenta Nakama, Dai Ogata(Unknown), Keita Tsutsui(Fukuoka University), Yusuke Muto
Cited by 24
Related Papers
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
|Nature Immunology|2020|810
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2018|586
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|Cancer Cell|2022|338